Goldstein D E, Little R R, Wiedmeyer H M, England J D, Rohlfing C L, Wilke A L
Department of Child Health, University of Missouri-Columbia School of Medicine 65212.
Clin Chem. 1994 Aug;40(8):1637-40.
To address the question, Do laboratory tests cost money or save money? we have used as a model for discussion a common chronic disease, diabetes mellitus, and a widely used laboratory test, that for glycohemoglobin, a measure of long-term glycemia used to manage diabetic patients. Diabetes mellitus is serious, highly prevalent, and costly. In 1992, $1 of every $7 spent on health in the US was for diabetes, predominantly for treatment of the chronic complications of the disease. The recently completed Diabetes Control and Complications Trial (DCCT) demonstrated that development and progression of the chronic complications of diabetes are related to the degree of altered glycemia as quantified by determinations of glycohemoglobin. Thus, use of glycohemoglobin testing for routine diabetes care provides an objective measure of a patient's risk for developing diabetic complications. Results of this test can alert patients and health providers to the need for change in the treatment plan. Optimal use of glycohemoglobin testing for diabetes care will require standardization of test results.
为了回答“实验室检查是耗费金钱还是节省金钱?”这个问题,我们以一种常见的慢性病——糖尿病,以及一种广泛使用的实验室检查——糖化血红蛋白检测(用于管理糖尿病患者的长期血糖水平的一项指标)作为讨论模型。糖尿病病情严重、极为常见且费用高昂。1992年,美国每7美元的医疗支出中就有1美元用于糖尿病,主要用于治疗该疾病的慢性并发症。最近完成的糖尿病控制与并发症试验(DCCT)表明,糖尿病慢性并发症的发生和发展与糖化血红蛋白测定所量化的血糖改变程度相关。因此,将糖化血红蛋白检测用于常规糖尿病护理可客观衡量患者发生糖尿病并发症的风险。该检测结果可提醒患者和医疗服务提供者有必要改变治疗方案。要在糖尿病护理中最佳地使用糖化血红蛋白检测,就需要使检测结果标准化。